Literature DB >> 22102711

Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma.

Alboukadel Kassambara1, Dirk Hose, Jérôme Moreaux, Brian A Walker, Alexei Protopopov, Thierry Reme, Franck Pellestor, Véronique Pantesco, Anna Jauch, Gareth Morgan, Hartmut Goldschmidt, Bernard Klein.   

Abstract

BACKGROUND: Genetic abnormalities are common in patients with multiple myeloma, and may deregulate gene products involved in tumor survival, proliferation, metabolism and drug resistance. In particular, translocations may result in a high expression of targeted genes (termed spike expression) in tumor cells. We identified spike genes in multiple myeloma cells of patients with newly-diagnosed myeloma and investigated their prognostic value. DESIGN AND METHODS: Genes with a spike expression in multiple myeloma cells were picked up using box plot probe set signal distribution and two selection filters.
RESULTS: In a cohort of 206 newly diagnosed patients with multiple myeloma, 2587 genes/expressed sequence tags with a spike expression were identified. Some spike genes were associated with some transcription factors such as MAF or MMSET and with known recurrent translocations as expected. Spike genes were not associated with increased DNA copy number and for a majority of them, involved unknown mechanisms. Of spiked genes, 36.7% clustered significantly in 149 out of 862 documented chromosome (sub)bands, of which 53 had prognostic value (35 bad, 18 good). Their prognostic value was summarized with a spike band score that delineated 23.8% of patients with a poor median overall survival (27.4 months versus not reached, P<0.001) using the training cohort of 206 patients. The spike band score was independent of other gene expression profiling-based risk scores, t(4;14), or del17p in an independent validation cohort of 345 patients.
CONCLUSIONS: We present a new approach to identify spike genes and their relationship to patients' survival.

Entities:  

Mesh:

Year:  2011        PMID: 22102711      PMCID: PMC3347668          DOI: 10.3324/haematol.2011.046821

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  41 in total

1.  High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.

Authors:  Daniel R Carrasco; Giovanni Tonon; Yongsheng Huang; Yunyu Zhang; Raktim Sinha; Bin Feng; James P Stewart; Fenghuang Zhan; Deepak Khatry; Marina Protopopova; Alexei Protopopov; Kumar Sukhdeo; Ichiro Hanamura; Owen Stephens; Bart Barlogie; Kenneth C Anderson; Lynda Chin; John D Shaughnessy; Cameron Brennan; Ronald A Depinho
Journal:  Cancer Cell       Date:  2006-04       Impact factor: 31.743

2.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

3.  Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.

Authors:  Bart Barlogie; Guido Tricot; Erik Rasmussen; Elias Anaissie; Frits van Rhee; Maurizio Zangari; Athanasios Fassas; Klaus Hollmig; Mauricio Pineda-Roman; John Shaughnessy; Joshua Epstein; John Crowley
Journal:  Blood       Date:  2005-12-01       Impact factor: 22.113

4.  A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas.

Authors:  Said Assou; Tanguy Le Carrour; Sylvie Tondeur; Susanne Ström; Audrey Gabelle; Sophie Marty; Laure Nadal; Véronique Pantesco; Thierry Réme; Jean-Philippe Hugnot; Stéphan Gasca; Outi Hovatta; Samir Hamamah; Bernard Klein; John De Vos
Journal:  Stem Cells       Date:  2007-01-04       Impact factor: 6.277

5.  Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics.

Authors:  Friedrich W Cremer; Jelena Bila; Isabelle Buck; Mutlu Kartal; Dirk Hose; Carina Ittrich; Axel Benner; Marc S Raab; Ann-Cathrin Theil; Marion Moos; Hartmut Goldschmidt; Claus R Bartram; Anna Jauch
Journal:  Genes Chromosomes Cancer       Date:  2005-10       Impact factor: 5.006

6.  Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

Authors:  Hervé Avet-Loiseau; Florent Malard; Loic Campion; Florence Magrangeas; Catherine Sebban; Bruno Lioure; Olivier Decaux; Thierry Lamy; Laurence Legros; Jean-Gabriel Fuzibet; Mauricette Michallet; Bernadette Corront; Pascal Lenain; Cyrille Hulin; Claire Mathiot; Michel Attal; Thierry Facon; Jean-Luc Harousseau; Stephane Minvielle; Philippe Moreau
Journal:  Blood       Date:  2010-10-20       Impact factor: 22.113

7.  Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.

Authors:  Ichiro Hanamura; James P Stewart; Yongsheng Huang; Fenghuang Zhan; Madhumita Santra; Jeffrey R Sawyer; Klaus Hollmig; Maurizio Zangarri; Mauricio Pineda-Roman; Frits van Rhee; Federica Cavallo; Bart Burington; John Crowley; Guido Tricot; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-16       Impact factor: 22.113

8.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Authors:  John D Shaughnessy; Fenghuang Zhan; Bart E Burington; Yongsheng Huang; Simona Colla; Ichiro Hanamura; James P Stewart; Bob Kordsmeier; Christopher Randolph; David R Williams; Yan Xiao; Hongwei Xu; Joshua Epstein; Elias Anaissie; Somashekar G Krishna; Michele Cottler-Fox; Klaus Hollmig; Abid Mohiuddin; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Jeffrey Sawyer; Yazan Alsayed; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

9.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Authors:  Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

10.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Authors:  Christina M Annunziata; R Eric Davis; Yulia Demchenko; William Bellamy; Ana Gabrea; Fenghuang Zhan; Georg Lenz; Ichiro Hanamura; George Wright; Wenming Xiao; Sandeep Dave; Elaine M Hurt; Bruce Tan; Hong Zhao; Owen Stephens; Madhumita Santra; David R Williams; Lenny Dang; Bart Barlogie; John D Shaughnessy; W Michael Kuehl; Louis M Staudt
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

View more
  21 in total

1.  In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.

Authors:  Erming Tian; Jeffrey R Sawyer; Christoph J Heuck; Qing Zhang; Frits van Rhee; Bart Barlogie; Joshua Epstein
Journal:  Genes Chromosomes Cancer       Date:  2014-03-17       Impact factor: 5.006

2.  IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors.

Authors:  M Jourdan; M Cren; N Robert; K Bolloré; T Fest; C Duperray; F Guilloton; D Hose; K Tarte; B Klein
Journal:  Leukemia       Date:  2014-02-07       Impact factor: 11.528

Review 3.  The genetic architecture of multiple myeloma.

Authors:  Gareth J Morgan; Brian A Walker; Faith E Davies
Journal:  Nat Rev Cancer       Date:  2012-04-12       Impact factor: 60.716

4.  Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma.

Authors:  Matthieu Schoenhals; Alboukadel Kassambara; Jean-Luc Veyrune; Jerome Moreaux; Hartmut Goldschmidt; Dirk Hose; Bernard Klein
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

5.  Machine learning predicts treatment sensitivity in multiple myeloma based on molecular and clinical information coupled with drug response.

Authors:  Lucas Venezian Povoa; Carlos Henrique Costa Ribeiro; Israel Tojal da Silva
Journal:  PLoS One       Date:  2021-07-28       Impact factor: 3.240

6.  In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.

Authors:  Ken Maes; Eva De Smedt; Alboukadel Kassambara; Dirk Hose; Anja Seckinger; Els Van Valckenborgh; Eline Menu; Bernard Klein; Karin Vanderkerken; Jérôme Moreaux; Elke De Bruyne
Journal:  Oncotarget       Date:  2015-02-20

7.  Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients.

Authors:  Elias Bou Samra; Bernard Klein; Thérèse Commes; Jérôme Moreaux
Journal:  Oncotarget       Date:  2012-08

8.  Gene expression-based risk score in diffuse large B-cell lymphoma.

Authors:  Caroline Bret; Bernard Klein; Jérôme Moreaux
Journal:  Oncotarget       Date:  2012-12

9.  Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.

Authors:  Alboukadel Kassambara; Matthieu Schoenhals; Jérôme Moreaux; Jean-Luc Veyrune; Thierry Rème; Hartmut Goldschmidt; Dirk Hose; Bernard Klein
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

10.  CRNDE: A Long Non-Coding RNA Involved in CanceR, Neurobiology, and DEvelopment.

Authors:  Blake C Ellis; Peter L Molloy; Lloyd D Graham
Journal:  Front Genet       Date:  2012-11-29       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.